
Rockwell Medical, Inc.
RMTINASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$8.01
+US$0.46 · +6.02%
RMTI公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Sell
Trim exposure — unfavorable risk-reward
估值
50
Fair Value
动量
17
Strong Down
情绪
59
Mixed
风险韧性
23
High Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
- 行业
- Drug Manufacturers - Specialty & Generic
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- Mark Strobeck
- 上市以来
- 1998年1月27日
- 雇员
- 157
市场位置
- 成交量
- 2.58万
- 0.77× 平均值
- 平均成交量
- 3.35万
- 日均成交量
- 市值
- 3197.09万 USD
- 贝塔
- 1.62
- 市场参考 1
财务数据
财务快照
最近十二个月财务健康
- 奥特曼 Z 分数
- -7.62
- 皮奥特罗斯基 F 分数
- 5 共 9 个
财报历史与展望
- 最新财年每股收益
- -1.5
- 2025财年
- 最新财年收入
- 6925.8万 USD
- 2025财年 · 同比-31.76%
年度每股收益趋势
已公布业绩及可用的市场共识预期。
年度营收趋势
已公布业绩及可用的市场共识预期。
分析师评级
第三方分析师预期可能变化,并非 GoAI 建议。
分析师目标价
平均目标
US$20.00
上涨空间 146.91%价格历史记录不可用
最高:US$20.00平均的:US$20.00最低:US$20.00评级分布
16项评级RMTI 消息
RMTI同业公司
持有RMTI的ETF
报告持有此股票敞口的交易所交易基金。
继续GoAI的研究
在 GoAI 中研究RMTIresearch.disclaimer













